文献速递肝病消化道肿瘤与早癌

CAGE-B与SAGE-B模型在亚洲初治CHB患者恩替卡韦治疗中的预测效能

Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-06-06

本研究回顾性纳入734例2006至2011年开始恩替卡韦治疗且无HCC发生的初治慢性乙型肝炎患者,评估CAGE-B和SAGE-B模型预测HCC的效能。抗病毒治疗5年后中位肝硬度6.8 kPa,CAGE-B和SAGE-B中位评分分别为7.0和6.0;随访超过5年66例(9.0%)发生HCC。两模型7年和10年AUROC分别为0.764/0.785和0.799/0.802,高危组HCC累积发生率显著高于中低危组。

要点

  • CAGE-B与SAGE-B在亚洲初治CHB患者恩替卡韦治疗5年后预测HCC效能可接受。
  • SAGE-B的似然比χ2和线性趋势χ2高于CAGE-B,CAGE-B的AIC更高。
  • 两模型高危组HCC累积发生率显著高于中低危组(P < .05)。

核心结论

  • SAGE-B和CAGE-B在亚洲CHB患者抗病毒治疗5年后预测HCC均表现出可接受的效能。

研究设计与样本

  • 回顾性队列研究,纳入734例2006至2011年开始恩替卡韦治疗且随访超过5年无HCC发生的初治CHB患者。

主要发现

  • 抗病毒治疗5年后中位肝硬度为6.8 kPa,CAGE-B和SAGE-B中位评分分别为7.0和6.0。
  • 抗病毒治疗开始超过5年后,66例(9.0%)发生HCC。
  • CAGE-B和SAGE-B的AUROC在治疗7年时为0.764和0.785,10年时为0.799和0.802。
  • 按两模型风险分层,高危组HCC累积发生率显著高于中危和低危组(所有比较P < .05)。
  • SAGE-B的似然比χ2(76.2 vs 71.4)和线性趋势χ2(74.1 vs 58.6)高于CAGE-B,而CAGE-B的AIC更高(64.3 vs 50.3)。

临床怎么用

  • 在亚洲初治CHB患者恩替卡韦治疗5年后,可用CAGE-B或SAGE-B进行HCC风险分层。
  • SAGE-B在似然比和线性趋势上略优,CAGE-B的AIC更高,选择模型时可结合临床场景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Cirrhosis and age (CAGE-B) and stiffness and age (SAGE-B) models assess the risk of hepatocellular carcinoma (HCC) development in white patients with chronic hepatitis B (CHB) undergoing sustained antiviral therapy (AVT). Herein, we checked the predictive performance of these models in Asian patients with CHB. METHODS: We reviewed 734 treatment-naive patients with CHB who started entecavir between 2006 and 2011 and were followed up for more than 5 years without HCC development during AVT. The predictive performance of CAGE-B and SAGE-B models was calculated using area under the receiver operating characteristic curves (AUROCs). RESULTS: Median liver stiffness assessed using transient elastography after 5 years of AVT was 6.8 kPa. Median CAGE-B and SAGE-B models after 5 years of AVT were 7.0 and 6.0, respectively. More than 5 years after AVT initiation, 66 patients (9.0%) developed HCC. The AUROCs of the CAGE-B and SAGE-B models were 0.764 and 0.785 after 7 years and 0.799 and 0.802 after 10 years of AVT, respectively. The cumulative incidence of HCC was significantly higher in the high-risk groups according to CAGE-B and SAGE-B risk stratification than in the medium- and low-risk groups (P < .05 in all cases). The SAGE-B model showed a higher likelihood ratio (χ2) (76.2 vs 71.4) and linear trend (χ2) (74.1 vs 58.6) than the CAGE-B model, whereas the CAGE-B model showed higher Akaike information criteria (64.3 vs 50.3). CONCLUSIONS: Both SAGE-B and CAGE-B showed acceptable performance in predicting HCC after 5 years of AVT in Asian patients with CHB.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Chon HY, Lee JS, Lee HW, et al. Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B. Clin Gastroenterol Hepatol. 2021. PMID: 34091048. doi:10.1016/j.cgh.2021.06.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。